The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA181130(AIMP1 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: ×200)
The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using CSB-PA181130(AIMP1 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: ×200)
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Hela cells, hepG2 cells, A549 cells, 293T cells, Primary antibody: CSB-PA181130(AIMP1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期:
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途:
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Non-catalytic component of the multisynthase complex. Stimulates the catalytic activity of cytoplasmic arginyl-tRNA synthase. Binds tRNA. Possesses inflammatory cytokine activity. Negatively regulates TGF-beta signaling through stabilization of SMURF2 by binding to SMURF2 and inhibiting its SMAD7-mediated degradation. Involved in glucose homeostasis through induction of glucagon secretion at low glucose levels. Promotes dermal fibroblast proliferation and wound repair. Regulates KDELR1-mediated retention of HSP90B1/gp96 in the endoplasmic reticulum. Plays a role in angiogenesis by inducing endothelial cell migration at low concentrations and endothelian cell apoptosis at high concentrations. Induces maturation of dendritic cells and monocyte cell adhesion. Modulates endothelial cell responses by degrading HIF-1A through interaction with PSMA7.
基因功能參考文獻:
The increase of EMAP-II serum level reflects an endothelial dysfunction in type 1 diabetes, alteration of carbohydrate and lipid metabolism could influence of this pathway. PMID: 29537208
This study showed the potential of the anti-AIMP1 antibody as a therapeutic option for AD treatment. Also, the finding of an association of blood AIMP1 levels with the MMSE score. PMID: 27906773
systemic mRNA expression of AIMP1 strongly differentiated children who failed to achieve asthma control with triamcinolone administration PMID: 27665382
p43 induces both the mRNA and protein expression of IP-10. PMID: 27574027
Data indicate that AIMP1 downregulation using siRNA is a novel tool to restore TGF-beta signaling and thereby increases the chondrogenic potential of dedifferentiated/degenerated chondrocytes. PMID: 26890138
two homozygous missense variants, p.(Gly299Arg) and p.(Val176Gly), in the gene AIMP1 that co-segregated with the phenotype, are reported. PMID: 26173967
findings suggest EMAP II is elevated in type 1 diabetic patients, particularly those with micro-vascular complications; EMAP II levels are related to inflammation, glycemic control, albuminuria level of patients and the risk of micro-vascular complications PMID: 26142824
AIMp1 promotes the proliferation and migration of fibroblasts/endothelial cells and importantly, pro-inflammatory gene expression in monocytes/macrophages and dendritic cells. PMID: 26325028
Increased serum level of EMAP-II may be one of the pathways of endothelial dysfunction in type 1 diabetes. PMID: 27089716
AIMP1 appears to function as a novel inhibitor of PPARgamma that regulates adipocyte differentiation by preventing the transcriptional activation of PPARgamma. PMID: 25146391
Data indicate that HCV E2 glycoprotein interacts with cellular AIMP1/p43 protein and promotes cell surface expression of membrane glycoproteins gp96 and transforming growth factor beta TGF-beta signaling. PMID: 24816397
Data indicate that the N terminus of Pro-EMAP II binds to its C terminus, arginyl-tRNA synthetase, and the neurofilament light subunit. PMID: 25724651
EMAP2 is a multifunctional polypeptide with proinflammatory and antiangiogenic activity. (Review) PMID: 26040042
Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients PMID: 24395571
interactions between the N-terminal domains of ArgRS and AIMP1 are important for the catalytic and noncatalytic activities of ArgRS and for the assembly of the higher-order MSC protein complex with ArgRS-GlnRS-AIMP1 PMID: 25288775
vascular contribution to lung development and the implications that vascular mediators such as EMAP II have in distal lung formation during the vulnerable stage of alveolar genesis. PMID: 24619875
AIMP1 peptide promotes the proliferation of BMMSCs by activating the beta-catenin/TCF complex via FGFR2-mediated activation of Akt, which leads to an increase in mesenchymal stem cells in peripheral blood. PMID: 23672191
Downregulation of CD23 attenuated AIMP1-induced TNF-alpha secretion and AIMP1 binding. PMID: 22767513
EMAP-II transcripts are upregulated in tumour cells in hypoxic conditions. PMID: 23082492
EMAP II has specific intracellular effects, and that this intracellular function appears to antagonize its extracellular anti-angiogenic effects during fetal development and pulmonary disease progression. PMID: 22412987
we propose that AIMP1 effect on EC adhesion is mediated by the assembly of a cytoskeletal protein complex on the cytosolic face of the cell membrane PMID: 21416500
Decreased expression of AIMP1 in gastric and colorectal cancer tissues suggests that down-regulation of this protein may be related to inactivation of the tumor suppressor functions of AIMP proteins and might play a role in the development of GC and CRC. PMID: 21789020
EMAPII is elevated in the BALF of active smokers and patients with COPD. Expression was increased in COPD lungs and emphysema. PMID: 21576822
The known pathological functions together with abundant cellular accumulation in cerebral ischemia lesions suggest that EMAPII might contribute to pathophysiological consequences of cerebral ischemia. PMID: 21047177
Through genome-wide homozygosity mapping and mutation analysis, we demonstrated in all affected individuals a homozygous frameshift mutation that fully abrogates the main active domain of AIMP1 PMID: 21092922
autoantibodies of aminoacyl-tRNA synthetase can be used in the diagnosis of type I diabetes PMID: 20429837
LPS induces the dissociation of gp96 from AIMP1 by phosphorylation through TLR4/MyD88-mediated JNK activation, resulting in translocation of gp96 on the cell surface. PMID: 20510162
p43 is cleaved during apoptosis by calpains and released as a truncated protein that is harmless for the structure of the atherosclerotic plaque. PMID: 20413730
AIMP1 may exert its antitumor activity by inducing tumor-suppressing cytokines. After a single intravenous injection, AMP1 exhibited a low clearance showing a one-compartmental disposition. PMID: 19573982
These results suggest the potential interaction of p43/EMAP II with alpha-ATP synthase and its role in the proliferation of endothelial cells. PMID: 11741979
temporal variation in EMAP II expression in the human endometrium across the menstrual cycle and localize expression to glandular epithelial, endothelial, and stromal cells. Moreover, EMAP II expression is negatively regulated by PGE(2). PMID: 12161535
p43-induced TNF production was mediated by the activation of MAPK family members, ERK and p38 MAPK, and by IkappaB degradation leading to the activation of NFkappaB. PMID: 12543078
Expression of endothelial monocyte activating polypeptide II is increased after spinal cord injury (SCI), suggesting a role for EMAP II in the pathophysiology of secondary injury following SCI. PMID: 14588117
Membrane-bound and soluble EMAP-II appear to play multiple roles in the tumor microenvironment, one of which is to assist in immune evasion. PMID: 14688335
EMAP-II causes a dose-dependent inhibition of proliferation and apoptosis in Jurkat T cells and mitogen-activated peripheral blood mononuclear cells, suggesting that EMAP-II constitutes a component of a novel, immunosuppressive pathway in solid tumors PMID: 14982944
DOC1 might play a role in mediating some of the effects of EMAP-II on endothelial cells PMID: 15935955
EMAP II is cleaved by MMP-9, elastase, and cathepsin L. PMID: 16674941
Three-dimensional structure is projected from amino acid sequence. PMID: 17018011
suggest that the cleavage of p43 and its cellular delocalization PMID: 17303557
Arginyl t-RNA synthetase over-expression associates with a reduced AIMP1 secretion. Multicatalytic protease is involved in the generation of the mature cytokine, EMAP II. PMID: 17443684
serum EMAP-II levels are significantly higher in patients with NSCLC than in healthy subjects and suggest it is of potential prognostic value PMID: 18621627
Results suggest novel roles for EMAP II in modulating the migration of dendritic cells and suggest that these effects may modify Meth A tumor/host interactions. PMID: 18951814
Inhibition of VEGF signaling is one possible antiangiogenic mechanism of EMAP II, which may explain its in vivo antitumor activity and delineate therapeutic strategies to enhance anti-VEGF therapy to inhibit tumor growth. PMID: 19002109
one of the major anti-angiogenic functions of EMAP-II is exerted through its inhibition of the HIF-1alpha activities PMID: 19362550
EMAP-II plays an important role in endothelial cell dysfunction related to graft-versus-host disease after allogeneic stem cell transplantation. PMID: 19565673
this is the first report showing evidence for the chemoattractant properties of EMAPII on leech and human microglial cells PMID: 19917687
Expression of the cleaved EMAP-II form in tumour-biopsies correlates with a good response of melanoma patients to TNF-based ILP. PMID: 16615114
EMAP-II facilitates apoptotic signaling of TNF-R1 via mobilization of TRADD. PMID: 17051333